As of the first three quarters, there were 9 pharmaceutical stocks with a market value of 100 billion yuan, with Mindray Medical firmly in the top spot and Hengrui Medicine returning to a market value of 300 billion yuan. In terms of quantity, there were 4 more stocks compared with the first half of the year, with Aier Eye Hospital, Yunnan Baiyao, United Imaging Healthcare, and Wantai Biopharma returning to the 100 billion yuan market value echelon. Among the TOP20, 15 stocks have positive growth, with Hengrui Medicine, BeiGene, Yunnan Baiyao, Shanghai Pharmaceuticals, China Resources Sanjiu, Baili Tianheng and 10 other stocks growing at a rate of more than 10%; while in the first half of the year, only 6 stocks had positive growth, with 4 other stocks growing at a rate of more than 10%, including Shanghai Pharmaceuticals and China Resources Sanjiu.

Mindray Medical has firmly established itself as the top pharmaceutical stock with a market value of 355.2 billion yuan. The company's performance (revenue, net profit) has repeatedly hit new highs in recent years, maintaining a growth rate of more than 10%. In the first half of 2024, its revenue exceeded 20 billion yuan, and its net profit exceeded 7 billion yuan. At the same time, it also gave out nearly 5 billion yuan in cash dividends.

Hengrui Medicine has returned to the 300 billion yuan market value mark, with an increase of more than 10% this year.

Recently, Hengrui's new products have made another good news. On September 30, the company issued an announcement that its subsidiary Guangdong Hengrui Medicine's SHR-1905 injection was approved for clinical trials and will conduct clinical trials for asthma in adolescents aged 12-17 years old.

Prior to this, its subsidiary Tianjin Hengrui Medicine's Fluor[18F]metabolic injection, Shanghai Hengrui Medicine and Shandong Shengdi Medicine's HRS-2129 tablets were approved for clinical trials; Suzhou Shengdia Biopharmaceuticals' Ruilafupu-α injection and Ruikang trastuzumab injection were under review; Beijing Shengdi Pharmaceuticals and Suzhou Shengdia Biopharmaceuticals' SHR-1918 injection was included in the proposed breakthrough therapy varieties, etc.

The number of stocks with a decline of 50% or more was reduced to 6, and more than 100 stocks rose, of which 64 rose by more than 10%, Shuangcheng Pharmaceutical and Xiaofang Pharmaceutical both rose by more than 100%, Innot, Innosilicon, Shuoshi Bio, Chuanning Bio, Xiangxue Pharmaceutical, Zhejiang Pharmaceutical, Haisike, Notai Bio, and Huitai Medical all rose by more than 50%.

In the first half of the year, more than 90% of pharmaceutical stocks fell, 30 fell by 50% or more, and only 27 rose by more than 10%.

Shuangcheng Pharmaceutical is the fastest-growing pharmaceutical stock in the first three quarters, with more than 10 consecutive trading days of daily limit, and 5 announcements of abnormal stock trading fluctuations were issued during this period.

Prior to this (September 11), Shuangcheng Pharmaceutical issued a restructuring plan to cross-border acquire semiconductor company Aola Shares. After the completion of this transaction, Aola Shares will become a wholly-owned subsidiary of Shuangcheng Pharmaceutical. Shuangcheng Pharmaceutical will also shift from the production of chemically synthesized peptide drugs to the development, design and sales of analog chips and digital-analog hybrid chips in the semiconductor industry, and will divest pharmaceutical-related assets in the future.

On September 21, Shuangcheng Pharmaceutical disclosed the progress of major asset restructuring. On October 8-9, Shuangcheng Pharmaceutical's stock price continued to rise.

Xiaofang Pharmaceutical officially landed on the main board of the Shanghai Stock Exchange in August this year. Its main business has always focused on the research and development, production and sales of external medicines. Its products are mainly over-the-counter medicines, which are household medicines, covering digestive, skin and otorhinolaryngology categories.

In the future, Xiaofang Pharmaceutical will continue to increase investment in research and development and talent training, improve the degree of production automation, continuously create and launch new products, improve the marketing service system, increase market development efforts, expand business scale, comprehensively improve management level, and maintain its leading position in the field of domestic and foreign medicines. On October 8, the company's stock price rose by the daily limit; on October 9, it rose again by 4.01%.